Cerus (NASDAQ:CERS) Downgraded to Hold Rating by Wall Street Zen

Cerus (NASDAQ:CERS) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Separately, TD Cowen reissued a “buy” rating on shares of Cerus in a research note on Monday, January 12th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Cerus presently has an average rating of “Hold”.

Cerus Stock Performance

Shares of CERS opened at $1.93 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.73 and a quick ratio of 1.29. The firm’s 50 day moving average is $2.31 and its 200-day moving average is $1.84. Cerus has a 12-month low of $1.12 and a 12-month high of $2.95. The stock has a market capitalization of $370.89 million, a P/E ratio of -24.13 and a beta of 1.51.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The company had revenue of $64.58 million for the quarter, compared to analysts’ expectations of $59.31 million. Equities research analysts anticipate that Cerus will post -0.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Cerus

A number of institutional investors have recently modified their holdings of the company. AQR Capital Management LLC grew its stake in Cerus by 291.6% in the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after buying an additional 1,064,133 shares during the last quarter. Kotler Kevin bought a new stake in Cerus during the fourth quarter valued at about $2,084,000. UBS Group AG boosted its holdings in Cerus by 227.1% during the fourth quarter. UBS Group AG now owns 1,142,502 shares of the biotechnology company’s stock valued at $2,354,000 after acquiring an additional 793,244 shares during the period. Acadian Asset Management LLC grew its position in shares of Cerus by 38.6% in the second quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company’s stock valued at $3,710,000 after purchasing an additional 733,683 shares during the last quarter. Finally, Globeflex Capital L P acquired a new stake in shares of Cerus in the fourth quarter valued at about $1,076,000. Institutional investors own 78.37% of the company’s stock.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.